Literature DB >> 30474532

Systemic Lupus Erythematosus and Endothelial Dysfunction: A Close Relationship.

Edoardo Sciatti1, Ilaria Cavazzana2, Enrico Vizzardi1, Ivano Bonadei1, Micaela Fredi2, Mara Taraborelli3, Romina Ferizi1, Marco Metra1, Angela Tincani2, Franco Franceschini2.   

Abstract

BACKGROUND: Accelerated atherosclerosis, responsible for premature cardiovascular disease, has been estimated to develop or progress in 10% of systemic lupus erythematosus (SLE) patients each year and to be 6-fold more frequent in SLE compared with the general population. The mechanisms underlying accelerated atherosclerosis in SLE are complex and involve classical and "non-classical" cardiovascular risk factors. Subclinical and disseminated atherosclerosis is associated with endothelial dysfunction and arterial stiffness.
OBJECTIVE: The aim of this review is to analyze the association between SLE and endothelial dysfunction. RESULTS AND
CONCLUSION: Different mechanisms have been proposed to explain the prevalence of endothelial dysfunction in SLE, which are briefly reported in this review: impaired clearance of apoptotic cells, oxidative stress markers, B cell activation with different circulating autoantibodies, different subtypes of T lymphocytes, cytokine cascade. Several studies and meta-analyses show a significant trend towards a prevalence of subclinical accelerated atherosclerosis in patients with SLE compared with healthy controls, since childhood. Based on general considerations, we suggest a multidisciplinary management to assess endothelial dysfunction at the diagnosis of the disease and to periodically search for and treat the traditional cardiovascular risk factors. Prospective studies are needed to confirm the benefits of this management. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Endothelial dysfunction; SLE; T lymphocytes; angiogenic T cells; microvascular; regulatory T cells.

Year:  2019        PMID: 30474532     DOI: 10.2174/1573397115666181126105318

Source DB:  PubMed          Journal:  Curr Rheumatol Rev        ISSN: 1573-3971


  10 in total

Review 1.  Innate Immune Dysregulation in the Development of Cardiovascular Disease in Lupus.

Authors:  Gantsetseg Tumurkhuu; Erica Montano; Caroline Jefferies
Journal:  Curr Rheumatol Rep       Date:  2019-07-23       Impact factor: 4.592

2.  Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.

Authors:  Renata J M Engler; Emily Brede; Todd Villines; Marina N Vernalis
Journal:  Fed Pract       Date:  2019-11

3.  Complement Activation on Endothelial Cell-Derived Microparticles-A Key Determinant for Cardiovascular Risk in Patients with Systemic Lupus Erythematosus?

Authors:  Naomi Martin; Xiaodie Tu; Alicia J Egan; Cordula Stover
Journal:  Medicina (Kaunas)       Date:  2020-10-13       Impact factor: 2.430

4.  Multimorbidity among incident Finnish systemic lupus erythematosus patients during 2000-2017.

Authors:  Simo Kariniemi; Vappu Rantalaiho; Lauri J Virta; Kari Puolakka; Tuulikki Sokka-Isler; Pia Elfving
Journal:  Lupus       Date:  2020-10-22       Impact factor: 2.911

5.  Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation.

Authors:  Paul Marczynski; Myriam Meineck; Ning Xia; Huige Li; Daniel Kraus; Wilfried Roth; Tamara Möckel; Simone Boedecker; Andreas Schwarting; Julia Weinmann-Menke
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

Review 6.  Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.

Authors:  Emily Keyes; Madison Grinnell; Douglas Jacoby; Thomas Vazquez; DeAnna Diaz; Victoria P Werth; Kevin Jon Williams
Journal:  Int J Womens Dermatol       Date:  2021-09-09

7.  Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up.

Authors:  Dieneke Schonenberg-Meinema; Sandy C Bergkamp; Amara Nassar-Sheikh Rashid; Mariken P Gruppen; Maritza A Middelkamp-Hup; Wineke Armbrust; Koert Dolman; A Elisabeth Hak; Petra C E Hissink Muller; Marieke van Onna; Joost F Swart; Taco W Kuijpers; Sylvia S M Kamphuis; Vanessa Smith; J Merlijn van den Berg
Journal:  Lupus Sci Med       Date:  2022-02

Review 8.  Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases.

Authors:  Liala Moschetti; Silvia Piantoni; Enrico Vizzardi; Edoardo Sciatti; Mauro Riccardi; Franco Franceschini; Ilaria Cavazzana
Journal:  Front Med (Lausanne)       Date:  2022-04-08

9.  Long-term prognosis of vascular access in hemodialysis patients with systemic lupus erythematosus: a retrospective cohort study.

Authors:  Yung-Tai Chen; Chih-Ching Lin; Fan-Yu Chen; Chun-Fan Chen; Ann Charis Tan; Chia-Hao Chan; Fu-An Chen; Wen-Sheng Liu; Tz-Heng Chen; Shuo-Ming Ou; Szu-Yuan Li; Ming-Tsun Tsai
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

10.  Predictive Value of High ICAM-1 Level for Poor Treatment Response to Low-Dose Decitabine in Adult Corticosteroid Resistant ITP Patients.

Authors:  Chaoyang Li; Lizhen Li; Meng Sun; Jianzhi Sun; Linlin Shao; Miao Xu; Yu Hou; Jun Peng; Lin Wang; Ming Hou
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.